126 related articles for article (PubMed ID: 9659582)
1. Molecular comparison of human and mouse pulmonary adenocarcinomas.
Malkinson AM
Exp Lung Res; 1998; 24(4):541-55. PubMed ID: 9659582
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice.
Floyd HS; Jennings-Gee JE; Kock ND; Miller MS
Mol Carcinog; 2006 Jul; 45(7):506-17. PubMed ID: 16482519
[TBL] [Abstract][Full Text] [Related]
3. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.
Packenham JP; Taylor JA; White CM; Anna CH; Barrett JC; Devereux TR
Clin Cancer Res; 1995 Jul; 1(7):687-90. PubMed ID: 9816033
[TBL] [Abstract][Full Text] [Related]
4. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
5. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene.
Tao Q; Fujimoto J; Men T; Ye X; Deng J; Lacroix L; Clifford JL; Mao L; Van Pelt CS; Lee JJ; Lotan D; Lotan R
J Natl Cancer Inst; 2007 Nov; 99(22):1668-82. PubMed ID: 18000218
[TBL] [Abstract][Full Text] [Related]
6. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.
Fisher GH; Wellen SL; Klimstra D; Lenczowski JM; Tichelaar JW; Lizak MJ; Whitsett JA; Koretsky A; Varmus HE
Genes Dev; 2001 Dec; 15(24):3249-62. PubMed ID: 11751631
[TBL] [Abstract][Full Text] [Related]
7. Prevention of lung cancer progression by bexarotene in mouse models.
Wang Y; Zhang Z; Yao R; Jia D; Wang D; Lubet RA; You M
Oncogene; 2006 Mar; 25(9):1320-9. PubMed ID: 16247446
[TBL] [Abstract][Full Text] [Related]
8. Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma.
Iwakawa R; Kohno T; Anami Y; Noguchi M; Suzuki K; Matsuno Y; Mishima K; Nishikawa R; Tashiro F; Yokota J
Clin Cancer Res; 2008 Jun; 14(12):3746-53. PubMed ID: 18559592
[TBL] [Abstract][Full Text] [Related]
9. A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice.
Wang Y; Zhang Z; Lubet RA; You M
Oncogene; 2006 Feb; 25(8):1277-80. PubMed ID: 16247444
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of mouse lung tumors: association with tumor progression, lung development, and human lung adenocarcinomas.
Bonner AE; Lemon WJ; Devereux TR; Lubet RA; You M
Oncogene; 2004 Feb; 23(5):1166-76. PubMed ID: 14647414
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of p16INK4A inactivation in non small-cell lung cancers.
Gazzeri S; Gouyer V; Vour'ch C; Brambilla C; Brambilla E
Oncogene; 1998 Jan; 16(4):497-504. PubMed ID: 9484839
[TBL] [Abstract][Full Text] [Related]
12. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.
Wang Y; Zhang Z; Kastens E; Lubet RA; You M
Cancer Res; 2003 Aug; 63(15):4389-95. PubMed ID: 12907609
[TBL] [Abstract][Full Text] [Related]
13. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
14. Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer.
Sekine I; Takami S; Guang SG; Yokose T; Kodama T; Nishiwaki Y; Kinoshita M; Matsumoto H; Ogura T; Nagai K
Oncol Rep; 1998; 5(2):351-4. PubMed ID: 9468555
[TBL] [Abstract][Full Text] [Related]
15. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium.
Lerman MI; Minna JD
Cancer Res; 2000 Nov; 60(21):6116-33. PubMed ID: 11085536
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice.
Ritland SR; Rowse GJ; Chang Y; Gendler SJ
Cancer Res; 1997 Aug; 57(16):3520-5. PubMed ID: 9270023
[TBL] [Abstract][Full Text] [Related]
17. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
18. Reduced transcription of the RB2/p130 gene in human lung cancer.
Xue Jun H; Gemma A; Hosoya Y; Matsuda K; Nara M; Hosomi Y; Okano T; Kurimoto F; Seike M; Takenaka K; Yoshimura A; Toyota M; Kudoh S
Mol Carcinog; 2003 Nov; 38(3):124-9. PubMed ID: 14587097
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
[TBL] [Abstract][Full Text] [Related]
20. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
